Результаты поиска

Clonal hematopoiesis and its progression to myeloid neoplasms: insights into risk, biology, and therapeutic strategies.

Clonal hematopoiesis (CH) is defined by the clonal expansion of hematopoietic stem and progenitor cells harboring somatic mutations that confer a fitness advantage. CH is common with advancing age and becomes nearly ubiquitous in middle age. Although typically asymptomatic, CH is associated with an increased risk of hematologic malignancies particularly myeloid neoplasms (MN), diverse non-malignant conditions, and all-cause mortality. Over the past decade, research has provided major insights into the origins of CH. In addition to aging, CH is promoted by environmental exposures, inherited gen

Granulocyte Colony Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells: An Alternative Cellular Source for Chimeric Antigen Receptor Therapy.

Lymphocyte collection by apheresis for CAR-T production usually does not include blood mobilized using granulocyte colony stimulating factor (G-CSF) due to the widespread knowledge that it causes a decrease in the number and functionality of lymphocytes. However, it is used for stem cell transplant, which is a common treatment for hematological malignancies. The growing demand for CAR therapies (CAR-T and NK-CAR), both in research and clinics, makes it necessary to evaluate whether mobilized PBSC products may be potential candidates for use in such therapies. This review collects recent works

Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions.

Clinically, it is highly challenging to promote recovery in patients with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). Despite recent advances in understanding the underlying mechanisms of ALF and ACLF, standard medical therapy remains the primary therapeutic approach. Liver transplantation (LT) is considered the last option, and in several cases, it is the only intervention that can be lifesaving. Unfortunately, this intervention is limited by organ donation shortage or exclusion criteria such that not all patients in need can receive a transplant. Another option is to

Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.

Background/Objectives: Acute kidney injury (AKI) is a common complication across the cancer care continuum and can compromise kidney function, delay or interrupt anticancer therapy, and worsen renal and oncologic outcomes. This state-of-the-art narrative review examines conventional clinical risk scores and artificial intelligence (AI)- and machine learning (ML)-based approaches to AKI prediction in oncology and identifies priorities for clinical translation. Methods: We conducted iterative searches of PubMed and Google Scholar through July 2026 and screened reference lists of relevant primary

Harnessing Immune Response in Acute Myeloid Leukemia.

Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among the most innovative therapeutic options, cellular therapy has shown great results in different hematological malignancies such as acute lymphoblastic leukemia and lymphomas, with several products already approved for clinical use. However, despite the great interest in also expanding the application

UEG Week 2015 Poster Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Role of Frailty in Assessing Eligibility for CAR T-Cell Therapy in Haematology.

Background and objectivesFrailty is a key consideration in determining whether a patient is robust enough for CAR T-cell therapy; however, it should not represent a barrier to treatment. Our study aimed to describe the extent of research concerning frailty in haematology adult and paediatric patients being considered for CAR T-cell therapy and its potential impact on their eligibility.MethodsFollowing the Joanna Briggs Institute guidelines, we adopted a scoping review methodology. Our search was conducted across the databases CINAHL, Cochrane, Embase, Medline, PubMed, Google Scholar, clinicalt

Модулирование ренального фиброза: новая роль фактора роста гепатоцитов.

Введение и обоснование фактора роста Hepatocyte (HGF) является многофункциональным белком, связанным с ростом и расширением клеток. Известно, что HGF в значительной степени проявляется в почечной ткани и в ее роли в залечивании ран и распространении тканей. Эта обзорная статья была направлена на изучение патогенеза HGF в почечной фиброзе в дополнение к его связи с взаимосвязанными подстрекательскими заболеваниями, такими, как гипертония и диабет. 2025 - выявление и сопоставление исследований, посвященных взаимосвязи между почечным фиброзом и ГФУ в доклинических и клинических условиях. Полученн

TriCAM (NCT02976558) - a randomized controlled pilot study of complementary medicine in allogeneic stem cell transplantation to improve quality of life.

BACKGROUND: Allogeneic stem cell transplantation (aSCT) frequently leads to prolonged impaired quality of life (Qol) and depression. To reduce symptom burden and improve Qol, we implemented a complementary medicine approach (TriCAM). METHODS: In a randomized, controlled clinical trial (NCT02976558), we enrolled 36 patients undergoing aSCT. In addition to standard care, the intervention group received Traditional Chinese Medicine acupuncture (TCMA), music therapy (TaKeTiNa) and active clown role playing. FACT-G was used to assess Qol and HADS-D to asses anxiety and depression. We monitored safe

Совпадение в полном тексте источника
… The low incidence of bleeding complications may also reflect our institution’s platelet transfusion threshold of 10,000/μL (or 20,000/μL for patients with fever or elevated bleeding risk), which ensured patients were not profoundly thrombocytopenic during acupuncture sessions. …

The EHA Research Roadmap: Infections in Hematology.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Combination of IFN-α/Gm-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study.

Interferon alpha (IFN-α) has been used as a maintenance therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM) patients. In this study, we combined GM-CSF with IFN-α in order to improve IFN tolerance in post-ASCT myeloma patients. Primary aims were to evaluate myelotoxicity and effectiveness of this maintenance therapy. The treatment included 4 × 10(6) units of IFN-α and 125 μg/m(2) of GM-CSF given three times a week for twelve months. Twenty seven patients were enrolled within 120 days after ASCT. One patient discontinued treatment due to thrombocytopenia and seve

Biology and Diseases of Dogs

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study.

Chimeric Antigen Receptor-T (CAR-T) cell therapy is effective for relapsed/refractory B-acute lymphoblastic leukemia (r/r B-ALL) but is not universally available. We developed a novel humanized CD19-directed CAR-T (HCAR19) approved for Phase 1/1b/2 trials. Patients aged 3-25 years were enrolled with r/r B-ALL and ineligible for allogeneic stem cell transplant. Lymphodepletion utilized standard-dose fludarabine and cyclophosphamide. A 3 + 3 design testing 3 dose-ranges was used to determine Phase-2 Dose (P2D): Dose-A, 1 × 106 HCAR19 cells/kg, Dose-B, 3-5 × 106/kg, and Dose-C, 10-15 × 106/kg. Pr

Immune Effector Cell-Associated HLH-like Syndrome: A Review of the Literature of an Increasingly Recognized Entity.

Since CAR-T cell therapy was initially approved in 2017, its use has become more prevalent and so have its side effects. CAR-T-related HLH, also named immune effector cell-associated HLH-like syndrome (IEC-HS), is a rare but fatal toxicity if not recognized promptly. We conducted a review of the literature in order to understand the prevalence of IEC-HS as well as clarify the evolution of the diagnostic criteria and treatment recommendations. IEC-HS occurrence varies between CAR-T cell products and the type of malignancy treated. Diagnosis can be challenging as there are no standardized diagno

Field-Deployable Treatments For Leishmaniasis: Intrinsic Challenges, Recent Developments and Next Steps.

Leishmaniasis is a neglected tropical disease endemic primarily to low- and middle-income countries, for which there has been inadequate development of affordable, safe, and efficacious therapies. Clinical manifestations of leishmaniasis range from self-healing skin lesions to lethal visceral infection with chances of relapse. Although treatments are available, secondary effects limit their use outside the clinic and negatively impact the quality of life of patients in endemic areas. Other non-medicinal treatments, such as thermotherapies, are limited to use in patients with cutaneous leishman

Сбалансирую эффективность и безопасность в нескольких пациентах с миеломой, получающих B-камерную антигенную терапию CAR-Cell.

В качестве новаторского и эффективного метода лечения пациентов с повторной/неизлечимой миеломой (BCMA) вспыхнула антигенная терапия созревания (BCMA), которая была ориентирована на CAR T-клеточную терапию, что свидетельствует о высокой доле респондентов и продолжительной ремиссии. Однако его применение связано с широким спектром токсичных свойств, начиная от хорошо известных общих событий и кончая более редкими и менее хорошо описанными осложнениями. Всеобъемлющее понимание как общих, так и редких токсичных свойств имеет важнейшее значение для своевременного признания и регулирования в целях

Лейкемия в период беременности: диагностика и терапевтический подход (обзор).

Цель настоящего исследования заключается в оценке эпидемиологических, диагностических и терапевтических данных о гематологических заболеваниях в период беременности. Лейкемия в период беременности встречается редко, а литературные данные не являются обширными. Факторы риска, эпидемиология и патогенез этих заболеваний не разработаны в полной мере. Кроме того, имеется подробный доклад о осложнениях в период беременности и об общем (на три месяца) лечении этих заболеваний, в частности о стратегии их лечения. В настоящем исследовании описывается возможность обеспечения в будущем беременности у жен

Совпадение в полном тексте источника
… For this reason, erythrocyte and platelet transfusions are necessary, with desirable hemoglobin values >10 g/dl and platelet values >50,000/µl. CLL in pregnancy is related to diabetes mellitus, especially in women who receive corticosteroids and in intrauterine growth restriction ( 36 ). …

Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice.

Chemotherapy is frequently accompanied by several side effects, including nausea, diarrhea, anorexia and fatigue. Evidence from ours and other groups suggests that chemotherapy can also play a major role in causing not only cachexia, but also bone loss. This complicates prognosis and survival among cancer patients, affects quality of life, and can increase morbidity and mortality rates. Recent findings suggest that soluble factors released from resorbing bone directly contribute to loss of muscle mass and function secondary to metastatic cancer. However, it remains unknown whether similar mech

New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Ixazomib is the first oral proteasome inhibitor to be approved, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Approval was on the basis of results from the phase 3, double-blind, placebo-controlled TOURMALINE-MM1 study, which demonstrated a 35% improvement in progression-free survival with the all-oral combination of ixazomib plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone alone (median: 20.6 vs 14.7 months; hazard ratio: 0.74, p=0.012; median follow-up 14.7 months). The ad

Infectious Diseases

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.